Chaubey Alka 4

What Happened
Alka Chaubey, Chief Medical Officer of Bionano Genomics (BNGO), was granted a derivative award for 27,737 shares on 2026-02-02. The Form 4 reports the acquisition at $0.00 (derivative), indicating an option-style award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-02; Form 4 filed: 2026-02-04 (appears timely).
• Transaction type/code: Award/Grant (A); derivative security.
• Amount: 27,737 shares reported at $0.00; total reported consideration $0.
• Vesting (Footnote F1): The option award vests monthly over 48 months starting one month after the vesting commencement date and is fully vested/exercisable on the four‑year anniversary.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context
This was a compensation grant (an option-style derivative award) that will convert to exercisable rights to acquire shares only as it vests; it is not an immediate market purchase or sale. Such grants are common executive compensation and do not by themselves signal a buy or sell decision by the insider.